Healthcare + Tech: Breaking Down DTEC’s Winning Formula

Both the healthcare and technology sectors appear poised for more upside in 2021. With the  ALPS Disruptive Technologies ETF (CBOE: DTEC) , investors don’t have to choose between the two. DTEC tracks the Indxx Disruptive Technologies Index, which identifies companies using disruptive technologies across ten thematic areas, including Healthcare Innovation, Internet of Things, Clean Energy and Smart Grid, Cloud Computing, Data and Analytics, FinTech, Robotics, Artificial Intelligence, Cybersecurity, 3D Printing, and Mobile Payments.

Don’t Miss Out on ‘EDOC’, a Novel Telemedicine ETF

Social distancing is helping to push the needle toward more telemedicine, which bodes well for ETFs like the Global X Telemedicine and Digital Health ETF (EDOC) . The fund is up 9% to start 2021. “Once considered to be merely a novel way to connect doctors with patients, telemedicine now is recognized as an essential tool in the fight to overcome Covid-19,” a Forbes article noted. “Since the start of this pandemic, there has been a nationwide push for treating non-emergency physical and mental illnesses with virtual office visits.

Examining 2021 Prospects for the Notorious ARKK ETF

It’s now the largest actively managed exchange traded of any variety, and its one of the best-performing ETFs this year, active or passive. The ARK Innovation ETF ( ARKK ) didn’t get here by chance. ARKK is often highlighted for being an early ETF advocate for Tesla ( NASDAQ : TSLA ). The case for Tesla upside remains strong because of continuous advancements in EV. “Electric vehicles may cost about the same as their gas-guzzling brethren in just three or four years — and only get cheaper from there,” reports David Baker for Bloomberg .

DGRW: Pfizer’s Vaccine News Could Set This ETF Into Motion

The WisdomTree U.S. Quality Dividend Growth ETF ( DGRW ) focuses on the dividend growth & quality factors and could be uniquely positioned to outperform in a post-vaccine world Positioning For The Re-Opening Rally The news of Pfizer’s potential coronavirus vaccine yielding very encouraging results in the early findings of its clinical trial was more than enough to send investors racing into risk assets betting that a full economic recovery could be on the way.
Instead, DGRW looks at long-term earnings growth expectations as a proxy for a company’s ability to continue paying and growing its dividend over time.

1 14 15 16 17